BioMarin Sees $1.50 Q3 EPS Hit From Alesta Costs Ahead of Results
Photo: TokenPost
BioMarin Pharmaceutical Inc. expects costs tied to its Alesta Therapeutics acquisition to reduce third-quarter 2026 diluted earnings per share by about $1.50, giving investors a preliminary measure of the deal’s effect ahead of its Nov. 2 results webcast. The quarterly estimate includes about $283 million in pretax acquired in-process research and development expense. BioMarin also expects ongoing operating expenses related to Alesta to contribute to the per-share reduction. The estimated impact is about $1.50 on both GAAP and non-GAAP diluted EPS. The company cautioned that its quarter-end financial close was incomplete and final figures could differ.
Source: TokenPost
